Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 1;16(12):2905-2912.
doi: 10.1080/21645515.2020.1820808. Epub 2020 Nov 24.

Recombinant vaccines for COVID-19

Tushar Yadav  1 , Nishant Srivastava  2 , Gourav Mishra  2 , Kuldeep Dhama  3 , Swatantra Kumar  4 , Bipin Puri  4 , Shailendra K Saxena  4
Affiliations
Review

Recombinant vaccines for COVID-19

Tushar Yadav et al. Hum Vaccin Immunother. .

Abstract

SARS-CoV-2, the causative agent of COVID-19, has imposed a major public health threat, which needs effective therapeutics and vaccination strategies. Several potential candidate vaccines being rapidly developed are in clinical evaluation. Considering the crucial role of SARS-CoV-2 spike (S) glycoprotein in virus attachment, entry, and induction of neutralizing antibodies, S protein is being widely used as a target for vaccine development. Based on advances in techniques for vaccine design, inactivated, live-vectored, nucleic acid, and recombinant COVID-19 vaccines are being developed and tested for their efficacy. Phase3 clinical trials are underway or will soon begin for several of these vaccines. Assuming that clinical efficacy is shown for one or more vaccines, safety is a major aspect to be considered before deploying such vaccines to the public. The current review focuses on the recent advances in recombinant COVID-19 vaccine research and development and associated issues.

Keywords: COVID-19; SARS-CoV-2; efficacy and safety; recombinant vaccine; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest. The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1.
Figure 1.
Various strategies for recombinant vaccine development. (a) DNA-based vaccine developed by cloning SARS-CoV-2 S-protein; (b) Development of vaccine using DNA plasmid containing SARS-CoV-2 S gene; (c) Vaccine development by S protein mRNA; (d) Use of recombinant S-protein mimicking SARS-Cov-2 S protein as a vaccine; (e) Use of vector without self-replicating machinery containing SARS-CoV-2 S protein gene as vaccine; (f) Virus-Like Particle equivalent to SARS-CoV-2 without genetic material as a vaccine. Most of the vaccines target S protein that is expected to sensitize the host cellular and humoral immune response leading to immunization
See this image and copyright information in PMC

References

    1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, et al. Coronaviridae study group of the international committee on taxonomy of viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5: 536–44. - PMC - PubMed
    1. Phelan AL, Katz R, Gostin LO.. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709–10. doi: 10.1001/jama.2020.1097. - DOI - PubMed
    1. WHO . World-health-organization coronavirus disease (COVID-19) outbreak; 2020. [accessed 2020 Jan 31 https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
    1. Srivastava N, Baxi P, Ratho RK, Saxena SK.. Global trends in epidemiology of coronavirus disease 2019 (COVID-19). In: Saxena SK, editor. Coronavirus disease 2019 (COVID-19): epidemiology, pathogenesis, diagnosis, and therapeutics. Singapore: Springer Singapore; 2020. p. 9–21.
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382(13):1199–207. doi: 10.1056/NEJMoa2001316. - DOI - PMC - PubMed

MeSH terms